BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma

计划入组 15 人 · 首次发布于 2018 年 9 月 10 日

CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With DSA

计划入组 18 人 · 首次发布于 2026 年 3 月 5 日

Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM

计划入组 60 人 · 首次发布于 2024 年 7 月 16 日

anti-CD19/BCMA CAR-T cells

BCMA-GPRC5D-CAR-T

BG BCMA

Mister Car Wash

United States

T-Knife GmbH

Germany

PH & T SpA

Italy

BCMA-Targeted CAR-T Therapy Achieves 96.3% Response Rate in Relapsed Multiple Myeloma Study

IASO Bio Receives Japanese Regulatory Approval for BCMA CAR-T Clinical Trial

BCMA CAR-T Therapy Combined with Pomalidomide Shows Promise in Multiple Myeloma Treatment